-
EP4313121
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4313121
| EP4313121 - DOSING AND ADMINISTRATION OF RECOMBINANT L-ASPARAGINASE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 05.01.2024 Database last updated on 12.06.2024 | |
| Former | The international publication has been made Status updated on 10.10.2022 | ||
| Former | unknown Status updated on 06.05.2022 | Most recent event Tooltip | 07.06.2024 | Change: Validation states | published on 10.07.2024 [2024/28] | 07.06.2024 | Change - extension states | published on 10.07.2024 [2024/28] | Applicant(s) | For all designated states Jazz Pharmaceuticals Ireland Ltd. Fifth Floor, Waterloo Exchange Waterloo Road 4 Dublin / IE | [2024/06] | Inventor(s) | 01 /
CHOI, Mi Rim Encino, California 91316 / US | 02 /
LIN, Tong Palo Alto, California 94303 / US | 03 /
SILVERMAN, Jeffrey Burlingame, California 94010 / US | [2024/06] | Representative(s) | Lee, Nicholas John, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2024/06] | Application number, filing date | 22719079.0 | 30.03.2022 | [2024/06] | WO2022US22635 | Priority number, date | US202163168224P | 30.03.2021 Original published format: US 202163168224 P | [2024/06] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022212571 | Date: | 06.10.2022 | Language: | EN | [2022/40] | Type: | A1 Application with search report | No.: | EP4313121 | Date: | 07.02.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.10.2022 takes the place of the publication of the European patent application. | [2024/06] | Search report(s) | International search report - published on: | EP | 06.10.2022 | Classification | IPC: | A61K38/50, A61K45/06, A61P35/02 | [2024/06] | CPC: |
A61K38/50 (EP,KR,US);
A61K45/06 (EP,KR,US);
A61K47/60 (US);
A61K9/0019 (US);
A61P35/00 (KR,US);
A61P35/02 (EP,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/06] | Title | German: | DOSIERUNG UND VERABREICHUNG VON REKOMBINANTER L-ASPARAGINASE | [2024/06] | English: | DOSING AND ADMINISTRATION OF RECOMBINANT L-ASPARAGINASE | [2024/06] | French: | DOSAGE ET ADMINISTRATION DE L-ASPARAGINASE RECOMBINANTE | [2024/06] | Entry into regional phase | 21.09.2023 | National basic fee paid | 21.09.2023 | Designation fee(s) paid | 21.09.2023 | Examination fee paid | Examination procedure | 21.09.2023 | Examination requested [2024/06] | 21.09.2023 | Date on which the examining division has become responsible | 07.05.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 03.01.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]EP3418383 (XL PROTEIN GMBH [DE], et al) [Y] 1-115 * paragraphs [0131] , [ 161]; example 8 *; | [Y]WO2020014581 (CHILDRENS MEDICAL CT CORP [US]) [Y] 1-115* paragraph [0145]; claims 1-7 *; | [IP]WO2021078988 (JAZZ PHARMACEUTICALS IRELAND LTD [IE]) [IP] 1-115 * paragraph [0255]; claims 1-73,222-227 *; | [I] - LYNDA M. VROOMAN ET AL, "Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E.coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia", PEDIATRIC BLOOD AND CANCER, US, (20150916), vol. 63, no. 2, doi:10.1002/pbc.25757, ISSN 1545-5009, pages 228 - 233, XP055747148 [I] 1-115 * abstract * DOI: http://dx.doi.org/10.1002/pbc.25757 | [I] - LIN T, "Population pharmacokinetic (PK) model development and simulation for recombinant crisantaspase produced in pseudomonas fluorescens (RC-P)", CLINICAL PHARMACOLOGY AND THERAPEUTICS, (20200101), vol. 107, no. S1, pages S93 - S94, XP055870146 [I] 1-115 * the whole document * | [I] - HERNANDEZ-ILLAS MARTHA ET AL, "A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20191113), vol. 134, doi:10.1182/BLOOD-2019-123695, ISSN 0006-4971, page 3817, XP086674993 [I] 1-115 * the whole document * DOI: http://dx.doi.org/10.1182/blood-2019-123695 | [I] - BEATA ZALEWSKA-SZEWCZYK ET AL, "The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations", CLINICAL AND EXPERIMENTAL MEDICINE, SPRINGER-VERLAG, MI, (20090130), vol. 9, no. 2, ISSN 1591-9528, pages 113 - 116, XP019664932 [I] 1-115 * Abstract, "Patient eligibility and treatment schedules"; page 114 * | [A] - SINDHU R ET AL, "Expression and characterization of recombinantl-asparaginase fromPseudomonas fluorescens", PROTEIN EXPRESSION AND PURIFICATION, (2017), vol. 143, doi:10.1016/J.PEP.2017.09.009, ISSN 1046-5928, pages 83 - 91, XP085322762 [A] 1-115 * abstract * DOI: http://dx.doi.org/10.1016/j.pep.2017.09.009 | by applicant | US4179337 | US5252714 | US5672662 | US6113906 | US2003114647 | WO2004083258 | EP1773452 | WO2007103290 | US7419600 | WO2011003886 | US2016244525 | US9920311 | WO2018234492 | US10174302 | US2019127742 | WO2019109018 | WO2021078988 | - MASHBURN, L.WRISTON, J., "Tumor Inhibitory Effect of L-Asparaginase", Biochem Biophys Res Commun, (19630000), vol. 12, doi:10.1016/0006-291X(63)90412-1, page 50, XP024777955 DOI: http://dx.doi.org/10.1016/0006-291X(63)90412-1 | - AGHAIPOUR, Biochemistry, (20010000), vol. 40, pages 5655 - 5664 | - PAPAGEORGIOU, FEBS J, (20080000), vol. 275, pages 4306 - 4316 | - KOTZIA, J. Biotechnol., (20070000), vol. 127, pages 657 - 669 | - MOOLA, Biochem. J., (19940000), vol. 302, pages 921 - 927 | - D. SCHRIJVERS et al., Clin. Pharmacokinet., (20030000), vol. 42, no. 9, pages 779 - 791 | - ZALEWSKA-SZEWCZYK, Clin. Exp. Med., (20090000), vol. 9, pages 113 - 116 | - AVRAMIS, Anticancer Research, (20090000), vol. 29, pages 299 - 302 | - RATANJI et al., "Immunogenicity of therapeutic proteins: Influence of Aggregation", Journal of Immunotoxicology, (20140000), vol. 11, no. 2, doi:10.3109/1547691X.2013.821564, pages 99 - 109, XP055576699 DOI: http://dx.doi.org/10.3109/1547691X.2013.821564 | - WANG et al., "Immunogenicity of Protein Aggregates-Concerns and Realities", International Journal of Pharmaceutics, (20120000), vol. 431, no. 1-2, pages 1 - 11 | - MOUSSA et al., "Immunogenicity of Therapeutic Protein Aggregates", Journal of Pharmaceutical Sciences, (20160000), vol. 105, no. 2, pages 417 - 430 | - "Uniprot", Database accession no. P00805 | - LIU, G., "Space for Calaspargase?", A New Asparaginase for Acute Lymphoblastic Leukemia Clin Cancer Res, (20200000), vol. 26, pages 325 - 7 | WO2021US32627 |